Vildagliptin For Type II Diabetes Can Be Combined With All Other Diabetes Drugs
This article was originally published in PharmAsia News
Partial changes to the efficacy and indication of Novartis Pharmaceuticals’ DPP-4 inhibitor drug Equa (vildagliptin) have been approved, the company announced on Feb. 28.
You may also be interested in...
The company said its own calculations suggest a mid-November readout could yield a positive result, keeping it on track for an EUA before the end of 2020.
With COVID-19 continuing to wreak havoc in the EU just as throughout the globe, the European Commission is proposing new measures that will impact antigen test availability and use
Amgen’s management took a deep dive into biosimilar market dynamics during the company’s third-quarter earnings call, as the California-based biotech continued to enjoy success for biosimilars in the US and Europe.